Trevor Allred
Stock Analyst at Oppenheimer
(4.69)
# 170
Out of 5,141 analysts
16
Total ratings
75%
Success rate
38.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Maintains: Outperform | $81 → $83 | $68.14 | +21.81% | 1 | Feb 13, 2026 | |
| LEGN Legend Biotech | Initiates: Outperform | $75 | $18.12 | +313.91% | 1 | Jan 7, 2026 | |
| DSGN Design Therapeutics | Initiates: Outperform | $18 | $10.11 | +78.04% | 1 | Jan 7, 2026 | |
| TBPH Theravance Biopharma | Initiates: Outperform | $27 | $19.66 | +37.33% | 1 | Dec 3, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $250 → $275 | $183.98 | +49.47% | 8 | Nov 7, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $80 | $34.79 | +129.95% | 2 | Sep 23, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $85 | $85.66 | -0.77% | 1 | Sep 9, 2025 | |
| INVA Innoviva | Initiates: Outperform | $35 | $23.39 | +49.64% | 1 | Aug 11, 2025 |
BridgeBio Pharma
Feb 13, 2026
Maintains: Outperform
Price Target: $81 → $83
Current: $68.14
Upside: +21.81%
Legend Biotech
Jan 7, 2026
Initiates: Outperform
Price Target: $75
Current: $18.12
Upside: +313.91%
Design Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $18
Current: $10.11
Upside: +78.04%
Theravance Biopharma
Dec 3, 2025
Initiates: Outperform
Price Target: $27
Current: $19.66
Upside: +37.33%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Outperform
Price Target: $250 → $275
Current: $183.98
Upside: +49.47%
MBX Biosciences
Sep 23, 2025
Maintains: Outperform
Price Target: $38 → $80
Current: $34.79
Upside: +129.95%
Palvella Therapeutics
Sep 9, 2025
Initiates: Outperform
Price Target: $85
Current: $85.66
Upside: -0.77%
Innoviva
Aug 11, 2025
Initiates: Outperform
Price Target: $35
Current: $23.39
Upside: +49.64%